---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-24-002189"
form_type: "8-K"
ticker: "PTCT"
cik: "0001070081"
company_name: "PTC THERAPEUTICS, INC."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:07:20.657446+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PTC Therapeutics 2023 revenue up 34% to $938M; guides 2024 revenue $600-680M

## Summary
- Total revenue $937.8M (+34% YoY); net loss $626.6M vs $559.0M in 2022.
- DMD franchise: Translarna $356M, Emflaza $255M; Evrysdi royalty + milestone $268.9M.
- Cash and securities $876.7M vs $410.7M a year ago; debt extinguishment loss $137.6M.
- Pipeline: sepiapterin MAA submission in Mar 2024, NDA by Q3 2024; vatiquinone NDA expected late 2024.
- 2024 guidance: total revenue $600-680M (down from $938M); GAAP R&D+SG&A $740-835M.

## SEC filing metadata
- accession: 0001558370-24-002189
- form_type: 8-K
- ticker: PTCT
- cik: 0001070081
- company_name: PTC THERAPEUTICS, INC.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/0001558370-24-002189-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/tmb-20240229x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-24-002189
- JSON: https://secwatch.observer/filing/0001558370-24-002189.json
- Plain text: https://secwatch.observer/filing/0001558370-24-002189.txt

## Key facts
- Earnings Releases
  PTC THERAPEUTICS, INC. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Revenue: Total revenue was $307.1 million for the fourth quarter of 2023... Total revenue was $937.8 million for full year 2023
  - Result: reported results
  source text: PTC Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1070081/000155837024002189/0001558370-24-002189-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.